Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners
SAM.GOV Due: October 18, 2028 at 04:00 PM UTC
Active Special Notice Source Url

Summary

The Generative Unconstrained Intelligence Drug Engineering (GUIDE) initiative is a collaborative effort involving U.S. interagency, academic, and industry partners aimed at accelerating the development of medical countermeasures for the warfighter. This program leverages advanced simulation and machine learning technologies to enhance the discovery and design of biological products, such as monoclonal antibodies and vaccines, as well as small molecule drugs. Contractors with expertise in computational and experimental platforms for drug development, particularly those with a focus on safety, efficacy, manufacturability, and pharmacokinetics, are encouraged to participate. The program is structured under a Participant Basic Agreement (PBA), and interested entities must demonstrate their technical relevance to the program to be considered for participation.
Description

W911SR-25-S-GUIDE

Notice Type: Special Announcement

Synopsis: This is a solicitation for parties interested in participating in projects sought by the The Joint Project Lead Chemical, Biological, Radiological, and Nuclear Defense Enabling

Entities
DOD
Department of Defense
DOTA
Department of the Army
NAICS
541715
Set Aside
None
Place of Performance
Frederick , Maryland 21702
Point of Contact
Full Name Email Phone Type
Joseph McCaffery [email protected] primary
Alexander Mayatte [email protected] secondary